Abivax (ABVX) Common Equity (2023 - 2025)
Historic Common Equity for Abivax (ABVX) over the last 3 years, with Q3 2025 value amounting to $597.7 million.
- Abivax's Common Equity changed N/A to $597.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $597.7 million, marking a year-over-year change of. This contributed to the annual value of $43.4 million for FY2024, which is 7954.61% down from last year.
- Per Abivax's latest filing, its Common Equity stood at $597.7 million for Q3 2025.
- Over the past 5 years, Abivax's Common Equity peaked at $597.7 million during Q3 2025, and registered a low of -$54.7 million during Q2 2025.
- Its 3-year average for Common Equity is $154.4 million, with a median of $89.8 million in 2024.
- Per our database at Business Quant, Abivax's Common Equity crashed by 7943.63% in 2024 and then plummeted by 14012.73% in 2025.
- Quarter analysis of 3 years shows Abivax's Common Equity stood at $210.9 million in 2023, then crashed by 79.44% to $43.4 million in 2024, then surged by 1278.13% to $597.7 million in 2025.
- Its Common Equity was $597.7 million in Q3 2025, compared to -$54.7 million in Q2 2025 and -$6.9 million in Q1 2025.